NeuroMetrix Provides Strategic Update
27 juin 2019 07h00 HE
|
NeuroMetrix, Inc.
WALTHAM, Mass., June 27, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), a health technology company addressing chronic health conditions including chronic pain, sleep disorders and...
NeuroMetrix Announces Issuance of New U.S. Patent for Quell Wearable Technology
21 mai 2019 13h00 HE
|
NeuroMetrix, Inc.
WALTHAM, Mass., May 21, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,293,159 titled “Measuring the...
NeuroMetrix Announces Issuance of New U.S. Patent for Quell Wearable Technology
07 mai 2019 13h00 HE
|
NeuroMetrix, Inc.
WALTHAM, Mass., May 07, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,279,179 titled...
NeuroMetrix Reports Q1 2019 Financial Results
25 avr. 2019 07h00 HE
|
NeuroMetrix, Inc.
WALTHAM, Mass., April 25, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), today reported financial and business highlights for the quarter ended March 31, 2019. The Company develops and...
NeuroMetrix, Inc. Announces Date for First Quarter 2019 Financial Results Conference Call
17 avr. 2019 11h00 HE
|
NeuroMetrix, Inc.
WALTHAM, Mass., April 17, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2019 first quarter financial results before the opening of the market...
NeuroMetrix Reports New Clinical Studies Published on DPNCheck
29 janv. 2019 13h00 HE
|
NeuroMetrix, Inc.
WALTHAM, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) today reported publication of three new DPNCheck® clinical studies. DPNCheck is a point-of-care test that provides...
NeuroMetrix Reports Q4 and Full Year 2018 Financial Results
24 janv. 2019 07h00 HE
|
NeuroMetrix, Inc.
WALTHAM, Mass., Jan. 24, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), today reported financial and business highlights for the quarter and year ended December 31, 2018. The...
NeuroMetrix Reports Publication of Randomized Controlled Trial of Quell Wearable Pain Relief in Chronic Low Back Pain
22 janv. 2019 13h00 HE
|
NeuroMetrix, Inc.
WALTHAM, Mass., Jan. 22, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) today reported publication of results from a randomized controlled trial of Quell® in subjects with chronic low back...
Quell Reports Successful CES 2019
16 janv. 2019 13h00 HE
|
NeuroMetrix, Inc.
WALTHAM, Mass., Jan. 16, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix (Nasdaq: NURO) today announced a successful CES 2019, the world’s largest and most influential technology event, which took place...
NeuroMetrix, Inc. Announces Fourth Quarter 2018 Financial Results Conference Call
15 janv. 2019 14h00 HE
|
NeuroMetrix, Inc.
WALTHAM, Mass., Jan. 15, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) will issue its fourth quarter 2018 financial results on Thursday morning January 24, 2019. A conference call will...